128 related articles for article (PubMed ID: 35405720)
1. Association Between Loss of SATB2 Expression in Inflammatory Bowel Disease Indefinite for Dysplasia and a Diagnosis of Definitive Dysplasia on Follow-up.
Cretara A; Knee A; Mueller J; Jawale R
Am J Surg Pathol; 2022 Aug; 46(8):1137-1141. PubMed ID: 35405720
[TBL] [Abstract][Full Text] [Related]
2. Loss of SATB2 Expression Is a Biomarker of Inflammatory Bowel Disease-associated Colorectal Dysplasia and Adenocarcinoma.
Ma C; Henn P; Miller C; Herbst C; Hartman DJ; Pai RK
Am J Surg Pathol; 2019 Oct; 43(10):1314-1322. PubMed ID: 31318711
[TBL] [Abstract][Full Text] [Related]
3. Colitis-associated colorectal adenocarcinomas are frequently associated with non-intestinal mucin profiles and loss of SATB2 expression.
Iwaya M; Ota H; Tateishi Y; Nakajima T; Riddell R; Conner JR
Mod Pathol; 2019 Jun; 32(6):884-892. PubMed ID: 30710095
[TBL] [Abstract][Full Text] [Related]
4. Loss of SATB2 Expression in Colorectal Carcinoma Is Associated With DNA Mismatch Repair Protein Deficiency and BRAF Mutation.
Ma C; Olevian DC; Lowenthal BM; Jayachandran P; Kozak MM; Chang DT; Pai RK
Am J Surg Pathol; 2018 Oct; 42(10):1409-1417. PubMed ID: 30001238
[TBL] [Abstract][Full Text] [Related]
5. SATB2 is a Promising Biomarker for Identifying a Colorectal Origin for Liver Metastatic Adenocarcinomas.
Zhang YJ; Chen JW; He XS; Zhang HZ; Ling YH; Wen JH; Deng WH; Li P; Yun JP; Xie D; Cai MY
EBioMedicine; 2018 Feb; 28():62-69. PubMed ID: 29396302
[TBL] [Abstract][Full Text] [Related]
6. Hypermucinous, Goblet Cell-Deficient and Crypt Cell Dysplasias in Inflammatory Bowel Disease are Often Associated with Flat/Invisible Endoscopic Appearance and Advanced Neoplasia on Follow-Up.
Choi WT; Salomao M; Zhao L; Alpert L; Setia N; Liao X; Drage MG; Westerhoff M; Cheng J; Lauwers GY; Ko HM
J Crohns Colitis; 2022 Jan; 16(1):98-108. PubMed ID: 34232295
[TBL] [Abstract][Full Text] [Related]
7. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
[TBL] [Abstract][Full Text] [Related]
8. Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract.
Giannico GA; Gown AM; Epstein JI; Revetta F; Bishop JA
Hum Pathol; 2017 Sep; 67():152-159. PubMed ID: 28711650
[TBL] [Abstract][Full Text] [Related]
9. SATB2 loss in inflammatory bowel disease-associated small intestinal metaplasia of the distal colon.
Zeineldin M; Larman TC
bioRxiv; 2023 Feb; ():. PubMed ID: 36778374
[TBL] [Abstract][Full Text] [Related]
10. Prior colorectal neoplasia is associated with increased risk of ileoanal pouch neoplasia in patients with inflammatory bowel disease.
Derikx LA; Kievit W; Drenth JP; de Jong DJ; Ponsioen CY; Oldenburg B; van der Meulen-de Jong AE; Dijkstra G; Grubben MJ; van Laarhoven CJ; Nagtegaal ID; Hoentjen F;
Gastroenterology; 2014 Jan; 146(1):119-28.e1. PubMed ID: 24076060
[TBL] [Abstract][Full Text] [Related]
11. SATB2 is a supplementary immunohistochemical marker to CDX2 in the diagnosis of colorectal carcinoma metastasis in an unknown primary.
Dabir PD; Svanholm H; Christiansen JJ
APMIS; 2018 Jun; 126(6):494-500. PubMed ID: 29924451
[TBL] [Abstract][Full Text] [Related]
12. The Role of SATB2 as a Diagnostic Marker of Sinonasal Intestinal-type Adenocarcinoma.
Skalova A; Sar A; Laco J; Metelkova A; Miesbauerova M; Steiner P; Švajdler M; Michal M
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):140-146. PubMed ID: 27258560
[TBL] [Abstract][Full Text] [Related]
13. Increased Risk of Non-conventional and Invisible Dysplasias in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease.
Zhang R; Lauwers GY; Choi WT
J Crohns Colitis; 2022 Dec; 16(12):1825-1834. PubMed ID: 35771958
[TBL] [Abstract][Full Text] [Related]
14. SATB2 in Neoplasms of Lung, Pancreatobiliary, and Gastrointestinal Origins.
De Michele S; Remotti HE; Del Portillo A; Lagana SM; Szabolcs M; Saqi A
Am J Clin Pathol; 2021 Jan; 155(1):124-132. PubMed ID: 32914850
[TBL] [Abstract][Full Text] [Related]
15. Young investigator challenge: Cadherin-17 and SATB2 in cytology specimens: Do these new immunostains help in differentiating metastatic colorectal adenocarcinoma from adenocarcinomas of other origins?
Brandler TC; Jelloul FZ; Soto D; Das K; Rosen L; Bhuiya TA
Cancer Cytopathol; 2015 Dec; 123(12):706-13. PubMed ID: 26671737
[TBL] [Abstract][Full Text] [Related]
16. Aberrant expression of maspin in idiopathic inflammatory bowel disease is associated with disease activity and neoplastic transformation.
Cao D; Wilentz RE; Abbruzzese JL; Ho L; Maitra A
Int J Gastrointest Cancer; 2005; 36(1):39-46. PubMed ID: 16227634
[TBL] [Abstract][Full Text] [Related]
17. Value of SATB2 immunostaining in the distinction between small intestinal and colorectal adenocarcinomas.
Kim CJ; Baruch-Oren T; Lin F; Fan XS; Yang XJ; Wang HL
J Clin Pathol; 2016 Dec; 69(12):1046-1050. PubMed ID: 27169755
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical characterization of appendiceal mucinous neoplasms and the value of special AT-rich sequence-binding protein 2 in their distinction from primary ovarian mucinous tumours.
Strickland S; Parra-Herran C
Histopathology; 2016 Jun; 68(7):977-87. PubMed ID: 26542609
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and treatment predictive significance of SATB1 and SATB2 expression in pancreatic and periampullary adenocarcinoma.
Elebro J; Heby M; Gaber A; Nodin B; Jonsson L; Fristedt R; Uhlén M; Jirström K; Eberhard J
J Transl Med; 2014 Oct; 12():289. PubMed ID: 25323550
[TBL] [Abstract][Full Text] [Related]
20. Morphological, immunohistochemical and molecular features of inflammatory bowel disease associated colorectal carcinoma and associated mucosal lesions - Single institution experience.
Kamarádová K; Vošmiková H; Rozkošová K; Ryška A; Tachecí I; Laco J
Pathol Res Pract; 2019 Apr; 215(4):730-737. PubMed ID: 30679085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
